Chronic Leukemias - Curative Intent Raises the Bar

Questions: Discounts, Updates etc.

Price: $3,800.00

Publication Date: 2005-10-07

Order Online Now

People that purchased this report also purchased:

Contact LeadDiscovery

  • If you have questions about this report
  • To find out if you qualify for a discount
  • Want a more up to date version
  • Can't find a report that meets your needs
Search all reports

Keywords:

Boolean terms AND, OR, NOT can be used. Phrases should be entered within quotes. For wildcards use an *

Recognizing that prolonging disease-free survival in chronic leukemia relies on the eradication of minimal residual disease has raised the bar for developers of novel pharmacotherapy. In meeting the more demanding success criteria and targeting innovative treatments to cohorts most likely to respond, developers should increasingly employ the use of molecular markers to guide risk stratification.


Scope

  • Overview of chronic leukemias including epidemiology, etiology, clinical features, staging and prognostic variables
  • Current treatment controversies and novel therapies in the developmental pipeline
  • Analysis of trial data, marketing factors and commercial potential for key technologies in clinical development
  • Stakeholder opinions and interview transcripts based on qualitative interviews with five opinion leaders from the US and Europe


    • Report Highlights
    Because of the heterogeneity of CLL there is a need to identify biological markers that provide a more robust and reliable prediction of patient outcomes to current and evolving treatment strategies. The identification and application of molecular markers to facilitate prognostication is becoming integral to the treatment decision-making process.

    The emergence of Gleevec-resistant CML, reported at rates of 4% with each year of treatment, coupled with only a 50% response rate in patients with advanced disease, indicate the need for novel, efficacious second-line treatment strategies both for patients with Gleevec-resistant chronic phase CML and for virtually all advanced stage patients.

    The goal for developers of novel CLL pharmacotherapy is to innovate drug treatments that can salvage patients refractory to alemtuzumab and improve on the former's toxicity while simultaneously increasing the rate and duration of minimal residual disease negativity.


    Reasons to Purchase

  • Identify opportunities for more efficacious second-line treatment strategies both for patients with Gleevec-resistant CML and advanced stage patients
  • Understand how future advancements in chronic leukemia prognostication have the potential to shift treatment paradigms
  • Assess opportunities and challenges facing innovative treatments for chronic leukemias, in particular the drive to eradicate minimal residual disease

    • Table of Contents

    Other users found this report page using the following search terms: leukemia cll chronic leukemia market treatment amn cml gleevec lymph male

    If you can't find a report that meets your needs contact LeadDiscovery. We are one of the few report providers with extensive drug development experience and we frequently use this knowledge to help clients source the most appropriate reports or produce reports for them from scratch.